Physician profile
Mohammad H Kabir
NPI 1326131715
$14,993.63
in general payments reported to CMS, 2019-2025
24 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 92% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,909 · 2020: $247 · 2021: $502 · 2022: $328 · 2023: $1,166 · 2024: $2,389 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,008.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $6,695.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,741.70 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $941.16 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $622.42 | 2019-2023 | Uzedy, Austedo Xr |
| Braeburn INC. | $492.55 | 2023-2024 | Brixadi |
| Lilly USA, LLC | $443.88 | 2019-2025 | Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $407.68 | 2019-2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $391.47 | 2019-2025 | Invega Sustenna |
| Amgen INC. | $359.85 | 2025 | Evenity, Uplizna, Krystexxa |
| Indivior INC. | $352.74 | 2019-2024 | Sublocade |
| Novo Nordisk INC | $345.88 | 2019-2025 | Ozempic |
| Vanda Pharmaceuticals INC. | $321.46 | 2024-2025 | Fanapt |
| Abiomed | $276.73 | 2023-2024 | Impella |
| Gilead Sciences, INC. | $266.01 | 2022-2023 | Epclusa |
| Supernus Pharmaceuticals, INC. | $264.92 | 2024-2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.51 | 2019-2024 | Spevigo |
| Alkermes, INC. | $142.29 | 2021-2022 | |
| Janssen Biotech, INC. | $125.01 | 2025 | Carvykti, Rybrevant |
| Akebia Therapeutics INC | $122.88 | 2025 | Vafseo |
| Avanir Pharmaceuticals, INC. | $122.55 | 2021 | |
| Sumitomo Pharma America, INC. | $107.46 | 2024 | Gemtesa |
| Pfizer INC. | $107.44 | 2019 | |
| Csl Behring | $100.00 | 2025 | Hizentra |
| Vertex Pharmaceuticals Incorporated | $22.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.